Oculis (OCS) H.C. Wainwright 28th Annual Global Investment Conference summary
Event summary combining transcript, slides, and related documents.
H.C. Wainwright 28th Annual Global Investment Conference summary
14 Sep, 2026Clinical development strategy
No major changes in clinical or financial criteria for advancing programs after DIAMOND trial; focus remains on execution and leveraging validated biomarkers for patient selection.
Licaminlimab and Privosegtor target different biological pathways, with Licaminlimab using TNFR1 biomarker enrichment for precision medicine in dry eye disease.
PREDICT-1 trial is enriched for TNFR1-positive patients, aiming for clinically meaningful improvements in ocular discomfort, with 4-8 point VAS score differences considered competitive.
Positive PREDICT-1 results would require at least one additional trial in signs before NDA submission, aligning with FDA expectations.
Restricting indication to biomarker-positive patients is viewed as an advantage, supporting a precision medicine approach and potentially higher revenues.
Diagnostic and regulatory considerations
Saliva-based qPCR assay for TNFR1 genotype is simple, rapid, and cost-effective, with turnaround as fast as one day in clinical practice.
FDA does not require a companion diagnostic, but ongoing validation in phase III trials is planned for future clinical use.
PIONEER program and expansion plans
PIONEER-1 focuses on optic neuritis, requiring rapid coordination among ER, neuro-ophthalmologists, and neurologists; lessons from phase II informed site activation.
Primary endpoint for regulatory approval is low contrast visual acuity (LCVA); structural markers like GCIPL and neurofilament strengthen the neuroprotection profile for future applications.
PIONEER-2 will focus on MS patients with acute relapses, aiming to expand the indication to broader acute MS relapses, increasing patient reach significantly.
Safety data from PIONEER-1 will be leveraged for acute MS relapse programs, with FDA support for using the same dose and regimen.
Latest events from Oculis
- Privosegtor advances neuroprotection while licaminlimab tests biomarker-guided dry-eye care.OCS
Stifel 2026 Healthcare Conference 2026 - PREDICT-1 readout nears as privosegtor advances across neuroprotection indications.OCS
3rd Annual Guggenheim Healthcare Innovation Conference - Late-stage trials advance as $252.0M in cash supports runway into 2H 2029.OCS
Q3 2026 - ACUITY signals support a registrational optic neuritis program for privosegtor.OCS
Euretina Innovation Spotlight (EIS) 2026 Presentation - TNFR1-guided dry-eye development targets greater benefit in biomarker-positive patients.OCS
Study presentation - Phase III programs in dry eye and optic neuritis advance, with MS and NAION expansion planned.OCS
2026 Global Healthcare Conference - Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth.OCS
Q2 2026 - Late-stage neuro-ophthalmic and ophthalmic programs advance toward pivotal milestones with strong financial backing.OCS
Corporate presentation - Positive clinical results and precision medicine advances set the stage for major milestones in 2024–2025.OCS
H.C. Wainwright 26th Annual Global Investment Conference